Clinical Trials

Do you have Narcolepsy? Interested in participating in a clinical trial?

SUVN-G3031 for Narcolepsy 1 or 2

Emmanuel Mignot, MD, PhD

Purpose: To study the safety and efficacy of study drug SUVN-G3031 as a possible treatment for NT1 and NT2

Inclusion:

  • 18-50 years old
  • Diagnosis of narcolepsy type 1 or 2
  • MSLT within 15 years showing ≤ 8 minutes with 2 or more SOREMPs
  • An ESS score of ≥ 12

Time needed from participant: Up to 7 weeks of active participation. At least 5 clinic visits during that period

Coordinator Contact:

Vivian Liu (650) 721-5489

vivian44@stanford.edu